Dardeer Khaled Tarek, Mohammed Khaled Ashraf, Hussein Tarek Dardeer, Elsheemy Mohammed Said
Medical Student, Faculty of Medicine, Cairo University, Cairo, Egypt.
Department of Zoology, Faculty of Science, Cairo University, Cairo, Egypt.
Indian J Urol. 2021 Jul-Sep;37(3):217-225. doi: 10.4103/iju.IJU_69_21. Epub 2021 Jul 1.
The emergence of urinary biomarkers for bladder cancer diagnosis could provide a reliable and less invasive diagnostic method. It could be also used as an adjuvant to the current gold standards of cytology and cystoscopy to improve diagnostic accuracy and decrease the percentage of false positives.
We searched PubMed, SCOPUS, and Web of Science up to March 18, 2020. We selected four studies that assessed the diagnostic accuracy of urinary apolipoprotein A1 (ApoA-1) in detecting bladder cancer and met the inclusion and exclusion criteria. Two authors independently extracted the data and performed quality assessment of the studies.
Four studies with 771 participants were selected; 417 were bladder cancer patients and 354 were controls. Bladder cancer was either transitional cell carcinoma or squamous cell carcinoma, the stages varied between Ta to T3, and the grades varied between G1 and G3. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 90.7%, 90%, 9.478, 0.1, and 99.424, respectively. Summary receiver operating characteristic curve showed an area under the curve of 0.9544 and Q* index of 0.8965.
ApoA-1 showed high sensitivity and specificity, so it could be a useful biomarker in diagnosis of bladder cancer.
用于膀胱癌诊断的尿液生物标志物的出现，可为膀胱癌提供一种可靠且侵入性较小的诊断方法。它还可作为当前细胞学和膀胱镜检查金标准的辅助手段，以提高诊断准确性并降低假阳性率。
我们检索了截至2020年3月18日的PubMed、SCOPUS和科学网。我们选择了四项评估尿载脂蛋白A1（ApoA-1）检测膀胱癌诊断准确性且符合纳入和排除标准的研究。两位作者独立提取数据并对研究进行质量评估。
选择了四项研究，共771名参与者；其中417名是膀胱癌患者，354名是对照。膀胱癌为移行细胞癌或鳞状细胞癌，分期从Ta到T3不等，分级从G1到G3不等。合并敏感度、特异度、阳性似然比、阴性似然比和诊断比值比分别为90.7%、90%、9.478、0.1和99.424。汇总的受试者工作特征曲线显示曲线下面积为0.9544，Q*指数为0.8965。
ApoA-1显示出高敏感度和特异度，因此它可能是诊断膀胱癌的一种有用生物标志物。
